达格列净治疗早期糖尿病肾病的疗效及对血清MCP-1、IL-6水平的影响

  目的  探讨达格列净治疗早期糖尿病肾病的疗效及对血清单核细胞趋化因子-1（MCP-1）、白细胞介素-6（IL-6）水平的影响。  方法  选择昆明医科大学第二附属医院于2019年1月至2020年1月期间收治的78例早期糖尿病肾病患者为研究对象，随机分为观察组与对照组，每组39例，2组均接受厄贝沙坦等常规治疗，对照组患者予二甲双胍降糖，观察组患者则应用达格列净降糖，疗程为12周。比较2组患者治疗前后血肌酐、空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血红蛋白（HbA1c）、尿白蛋白排泄率（UAER）以及血清MCP-1、IL-6水平的变化。  结果  治疗后，2组FBG、2 h PG及HbA1c均明显降低，且观察组均明显低于对照组，差异有统计学意义（P < 0.05）；治疗后，2组UAER较治疗前明显降低，且观察组低于对照组，差异有统计学意义（P < 0.05）；2组患者治疗前后血肌酐水平均无明显变化（P > 0.05）；治疗后，2组患者血清MCP-1、IL-6水平均较治疗前明显下降，且观察组明显低于对照组，差异有统计学意义（P < 0.05）。Peason相关性分析表明，早期糖尿病肾病患者UAER与血清MCP-1、IL-6水平均呈正相关性（P < 0.05）。  结论  达格列净应用于早期糖尿病肾病的治疗，不仅可以有效控制患者的血糖，还可以降低血清MCP-1、IL-6水平，减少尿蛋白的漏出，进而保护患者的肾功能。

Efficacy of Dapagliflozin on Early Diabetic Nephropathy and Its Effect on Serum MCP-1 and IL-6

  Objective  To investigate the effect of Dapagliflozin in the treatment of early diabetic nephropathy and its effect on serum MCP-1 and IL-6.   Methods  78 cases of patients with early diabetic nephropathy treated in our hospital from January 2019 to January 2020 were randomly divided into observation group and control group, with 39 cases in each group. Both groups received irbesartan and other conventional treatment. In addition, patients in the control group were treated with metformin, and patients in the observation group were treated with dagaglidine for 12 weeks. The changes of serum creatinine, fasting blood glucose （FBG）, 2 h postprandial blood glucose （2 h PG）, glycosylated hemoglobin （HbA1c）, urinary albumin excretion rate （UAER） and serum McP-1 and IL-6 levels in 2 groups were compared before and after treatment.   Results  After treatment, FBG, 2hPG and HbA1c in the two groups were significantly decreased, and the observation group was significantly lower than the control group （P < 0.05）. After treatment, UAER in both groups was significantly lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant （P < 0.05）. There was no significant change in serum creatinine level in 2 groups before and after treatment （P > 0.05）. After treatment, the serum LEVELS of McP-1 and IL-6 in 2 groups were significantly decreased compared with before treatment, and the observation group was significantly lower than the control group, the difference was statistically significant （P < 0.05）. Pearson correlation analysis showed that UAER was positively correlated with serum MCP-1 and IL-6 in early diabetic nephropathy patients （P < 0.05）.   Conclusion  The application of Dapagliflozin in the treatment of early diabetic kidney disease can not only effectively control the blood glucose, but also reduce the serum MCP-1 and IL-6, reduce the leakage of urine protein, and then protect the renal function.